M. Rojavin

T. Machnig, H. Farkas, J. Edelman, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Functional dyspepsia, delayed gastric emptying, and impaired quality of life

A. Zinsmeister, M. Camilleri, B. Lahr, 2005, Gut.

Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.

J. Edelman, M. Rojavin, I. Martínez-Saguer, 2017, Allergy and asthma proceedings.

Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates

J. Sleasman, M. Stein, M. Rojavin, 2010, Journal of Clinical Immunology.

Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

P. Soler-Palacín, M. Dorsey, M. Rojavin, 2014, Journal of Clinical Immunology.

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema

T. Machnig, J. Bernstein, W. Lumry, 2017, Allergy & rhinology.

Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry

J. Edelman, M. Rojavin, I. Martínez-Saguer, 2016, Drugs & Aging.

C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study

T. Machnig, T. Craig, R. Wasserman, 2011, Allergy.

Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.

T. Machnig, J. Bernstein, T. Craig, 2012, Allergy and asthma proceedings.

Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry.

T. Machnig, W. Lumry, P. Busse, 2015, The journal of allergy and clinical immunology. In practice.

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.

J. Bernstein, W. Lumry, P. Busse, 2016, The journal of allergy and clinical immunology. In practice.

Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks.

T. Machnig, J. Bernstein, T. Craig, 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.

J. Bernstein, W. Lumry, P. Busse, 2017, The journal of allergy and clinical immunology. In practice.

Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.

J. Bernstein, W. Lumry, P. Busse, 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency

J. Lawo, M. Rojavin, A. Hubsch, 2016, Journal of Clinical Immunology.

Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency

E. Haddad, M. Tortorici, M. Rojavin, 2019, Clinical pharmacology in drug development.

Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

R. Nelson, J. Church, R. Wasserman, 2011, Clinical pharmacokinetics.

Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency

T. Morio, M. Tortorici, M. Rojavin, 2019, Immunological medicine.

Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

P. Soler-Palacín, M. Dorsey, M. Rojavin, 2014, Journal of Clinical Immunology.

Effect of millimeter waves on survival of UVC-exposed Escherichia coli.

M. Ziskin, M. Rojavin, Mikhail Rojavin, 1995, Bioelectromagnetics.

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

M. Rojavin, M. Berger, P. Kiessling, 2011, Clinical immunology.

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

H. Kanegane, R. Nelson, K. Imai, 2018, Journal of Clinical Immunology.

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

H. Kanegane, R. Nelson, K. Imai, 2018, Journal of Clinical Immunology.

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies

H. Kanegane, S. Jolles, M. Rojavin, 2018, Journal of Clinical Immunology.

Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.

M. Tortorici, M. Rojavin, Dandan Luo, 2020, Clinical therapeutics.

Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency

C. Landersdorfer, C. Kirkpatrick, J. Edelman, 2013, Postgraduate medicine.

Erratum to: Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases

H. Kanegane, H. Takada, T. Hara, 2014, Journal of Clinical Immunology.

Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health‐related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety

C. A. Jones, M. Rojavin, J. Baggish, 2012 .

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

N. Patel, D. Vinh, V. Bonagura, 2021, Journal of Clinical Immunology.

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study

N. Patel, D. Vinh, V. Bonagura, 2020, Journal of clinical immunology.

Increased frequency of infections at the end of the IVIG dosing cycle: effect characterization from three Phase III studies

M. Rojavin, M. Berger, J. Baggish, 2012 .

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency

J. Lawo, M. Rojavin, A. Hubsch, 2016, Journal of Clinical Immunology.

Pharmacokinetic Modeling Predicts Different IgG Exposures Using Different IVIG-Scig Dose Conversion Factors In Patients With Primary Immune Deficiency

J. Edelman, M. Rojavin, J. Sidhu, 2014 .

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.

R. Nelson, R. Wasserman, J. Lawo, 2014, Clinical immunology.

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases

H. Kanegane, H. Takada, T. Hara, 2014, Journal of Clinical Immunology.

Long‐term safety of tegaserod in patients with constipation‐predominant irritable bowel syndrome

W. Snape, M. Rojavin, G. Tougas, 2002, Alimentary pharmacology & therapeutics.

Antipruritic effect of millimeter waves in mice: evidence for opioid involvement.

A Cowan, M C Ziskin, M. Ziskin, 1998, Life sciences.

Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.

T. Eisenstein, M. Adler, T. Rogers, 1993, The Journal of pharmacology and experimental therapeutics.

In Vivo Effects of Millimeter Waves on Cellular Immunity of Cyclophosphamide-Treated Mice

M. Ziskin, M. Rojavin, A. Tsygankov, 1997 .

Factors motivating dyspepsia patients to enter clinical research.

M. Rojavin, M. Shetzline, P. Downs, 2006, Contemporary clinical trials.

Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.

E. Haddad, M. Tortorici, M. Rojavin, 2019, International immunopharmacology.

Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study

T. Morio, J. Lawo, M. Rojavin, 2021, International Journal of Hematology.

Reactions of keratinocytes to in vitro millimeter wave exposure

M C Ziskin, M. Ziskin, T. Rogers, 2001, Bioelectromagnetics.

Hypoalgesic effect of millimeter waves in mice: dependence on the site of exposure.

A Cowan, M C Ziskin, S. Alekseev, 2000, Life sciences.

Suppression of pain sensation caused by millimeter waves: a double-blinded, cross-over, prospective human volunteer study.

A Cowan, M C Ziskin, M. Ziskin, 1999, Anesthesia and analgesia.

ReactionsofKeratinocytesto InVitro Millimeter Wave Exposure

M. Ziskin, T. Rogers, M. Rojavin, 2001 .

Reactions of Keratinocytes to InVitroMillimeter Wave Exposure

M. Ziskin, T. Rogers, M. Rojavin, 2022 .

Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod.

M. Rojavin, A. Cowan, D. Earnest, 2005, European journal of pharmacology.

Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency

M. Rojavin, M. Pfister, J. Sidhu, 2014, Clinical and experimental immunology.

Pain relief caused by millimeter waves in mice: results of cold water tail flick tests.

A Cowan, M C Ziskin, M. Ziskin, 2000, International journal of radiation biology.

Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.

J. Edelman, M. Rojavin, I. Martínez-Saguer, 2017, Allergy and asthma proceedings.

C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study

T. Machnig, M. Rojavin, R. Levy, 2011, Allergy.

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies

H. Kanegane, S. Jolles, M. Rojavin, 2018, Journal of Clinical Immunology.